ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BAYN Bayer AG

28.15
-0.13 (-0.46%)
03 May 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type
Bayer AG TG:BAYN Tradegate Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.13 -0.46% 28.15 28.08 28.22 28.49 27.81 28.345 232,091 22:50:04

Bayer Swung to Quarterly Loss on Litigation Provisions

04/08/2020 7:47am

Dow Jones News


Bayer (TG:BAYN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Bayer Charts.

By Kim Richters

 

Bayer AG Tuesday said it swung to a loss in the second quarter of the year, as it set aside provisions for settlements related to its glyphosate-based Roundup herbicide.

The German pharmaceutical and chemical conglomerate said its net loss for the period was 9.55 billion euros ($11.23 billion) due to special items for litigations, compared with a profit of EUR404 million a year earlier. Charges included costs for the Roundup cases as well as provisions for other litigations such as for the dicamba herbicide, the company said.

Bayer continues to expect total costs of up to $10.9 billion to settle the tens of thousands of lawsuits related to the Roundup herbicide and resolve possible future litigations.

Earnings before interest, taxes, depreciation and amortization before special items rose 5.6% to EUR2.88 billion, compared with EUR2.73 billion in the same quarter the previous year.

Quarterly sales came in at EUR10.05 billion down from EUR10.71 billion year prior.

Analysts expected sales of EUR10.40 billion and adjusted Ebitda of EUR2.74 billion, according to consensus estimates provided by Vara Research.

Bayer lowered its outlook for the year due to the coronavirus pandemic. It now expects sales to be between EUR43 billion and EUR44 billion and Ebitda before special items of around EUR12.1 billion, both on a currency-adjusted basis.

 

Write to Kim Richters at kim.richters@wsj.com

 

(END) Dow Jones Newswires

August 04, 2020 02:32 ET (06:32 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

1 Year Bayer Chart

1 Year Bayer Chart

1 Month Bayer Chart

1 Month Bayer Chart

Your Recent History

Delayed Upgrade Clock